Bernard Gilly (GenSight Biologics S.A. (Euronext: SIGHT))

Gilly, Bernard (GenSight Biologics 201304 CEO + Co-founder before Fovea + Sofinnova Partners + Transgene)

	Organisation	GenSight Biologics S.A. (Euronext: SIGHT)
	Former/major organisation	Fovea Pharmaceutical S.A.
	Group	Sanofi (Group) [since May 2011]
	Product	BIOTECH
	Product 2	venture capital

Record changed: 2024-02-12

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Bernard Gilly

[1] GenSight Biologics S.A.. (12/22/23). "Press Release: GenSight Biologics Appoints Laurence Rodriguez as Chief Executive Officer". Paris....
[2] GenSight Biologics S.A.. (11/21/23). "Press Release: GenSight Biologics Announces a Successful Offering for an Amount of approximately €4.7 Million". Paris....
[3] GenSight Biologics S.A.. (10/22/20). "Press Release: GenSight Biologics Successfully Raises €25 Million in an Oversubscribed Private Placement With US and European Institutional Investors". Paris....
[4] Tissium S.A.. (11/20/19). "Press Release: Tissium Closes €39M Series B Funding Round". Paris....
[5] GenSight Biologics S.A.. (4/3/18). "Press Release: GenSight Biologics Announces Topline Results from REVERSE Phase III Clinical Trial of GS010 in Patients with Leber Hereditary Optic Neuropathy (LHON)". Paris....
[6] GenSight Biologics S.A.. (8/1/17). "Press Relase: GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]